Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.75)
# 2,035
Out of 4,981 analysts
74
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $23.61 | -6.82% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $14.08 | +6.53% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $11.65 | -31.33% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $16.16 | +209.41% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $141.90 | -4.16% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $5.20 | +207.69% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $8.21 | +655.18% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $2.75 | +336.36% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $17.39 | +526.80% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $1.32 | +506.06% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.63 | +115.98% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $7.00 | +1,328.57% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $9.25 | -35.14% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.82 | +449.74% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $145.93 | -84.24% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $23.40 | +53.85% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $23.61
Upside: -6.82%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $14.08
Upside: +6.53%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $11.65
Upside: -31.33%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $16.16
Upside: +209.41%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $141.90
Upside: -4.16%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $5.20
Upside: +207.69%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $8.21
Upside: +655.18%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $2.75
Upside: +336.36%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $17.39
Upside: +526.80%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.32
Upside: +506.06%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.63
Upside: +115.98%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $7.00
Upside: +1,328.57%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $9.25
Upside: -35.14%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.82
Upside: +449.74%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $145.93
Upside: -84.24%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $23.40
Upside: +53.85%